02633 JACOBSON PHARMA
- 0.560
- -0.010-1.75%
JACOBSON PHARMA News
Zhitong Hong Kong Shareholders' Rights Disclosure | April 16
Disclosure of Hong Kong Stock Shareholders' Rights | April 16
Jacobson Pharma Raises HK$39 Million From Share Placement
Jacobson Pharma (HKG:2633) has completed the placement of 66 million shares to at least six investors at HK$0.60 apiece to raise net proceeds of around HK$38.8 million. The drugmaker will use the deal
Jacossen Pharmaceutical (02633) completed the placement of a total of 66 million shares
Jacochen Pharmaceutical (02633) issued an announcement. All conditions contained in the placement agreement have been met, and the placement has been completed on 20...
Jacobson Pharmaceuticals (02633.HK) plans to discount approximately 1.64% of the total placement of 66 million shares to raise approximately HK$38.8 million
Gelonghui, Feb. 19, 丨 Jacochen Pharmaceutical (02633.HK) announced that on February 19, 2024, the company signed a placement agreement with the placement agent. The company plans to place a total of 66 million shares, accounting for about 3.41% of the issued shares and about 3.30% of the issued share capital after the issuance was expanded. The placement price for each placed share is HK$0.60, which is approximately 1.64% off the closing price of HK$0.61 per share as reported on the date of the placement agreement. Assuming full distribution of the shares placed, the total proceeds from the placement would be approximately HK$39.6 million, and the net proceeds are expected to be around 3
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Jacobson Pharma's (HKG:2633) Profits Appear To Have Quality Issues
Jacobson Pharma Corporation Limited's (HKG:2633) robust recent earnings didn't do much to move the stock. However the statutory profit number doesn't tell the whole story, and we have found some fact
雅各臣科研製藥：二零二三年中期報告
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Jacobson Pharma Corporation Limited (HKG:2633) stock is about to trade ex-dividend in 4 days. The ex-dividend date is usually set to be one business day before the record date which is the cut-off da
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
JACOBSON PHARMA To Go Ex-Dividend On December 18th, 2023 With 0.025 HKD Dividend Per Share
November 24th - $JACOBSON PHARMA(02633.HK)$ is trading ex-dividend on December 18th, 2023. Shareholders of record on December 19th, 2023 will receive 0.025 HKD dividend per share on January 10th,
Jacobson Pharma Reports 42% Fiscal H1 Profit Growth; Shares Rise
Jacobson Pharma (HKG:2633) said total profit jumped some 42% in the six months through September 2023 to about HK$177.9 million, from an adjusted HK$125.3 million in the year-ago period. Basic earning
JACOBSON PHARMA: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Jacobson Research Pharmaceuticals (02633.HK) plans to hold a board meeting on November 24 to approve the interim results
Glonghui November 9 | Jacobson Research & Pharmaceuticals (02633.HK) announced that the board of directors would like to hold a board meeting on November 24, 2023 (Friday) to consider and approve the interim results of the company and its subsidiaries for the six months ended September 30, 2023 for publication, and to consider paying interim dividends (if any), and handling other matters.
Analysis
Price Target
No Data
